Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Michael Makris, Marcus Maurer & Torsten Zuberbier. (2013) Pharmacotherapy of chronic spontaneous urticaria. Expert Opinion on Pharmacotherapy 14:18, pages 2511-2519.
Read now
Read now
S Rico, RM Antonijoan & MJ Barbanoj. (2009) Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. Journal of Asthma and Allergy 2, pages 73-92.
Read now
Read now
Bettina Wedi & Alexander Kapp. (2005) Chronic urticaria: assessment of current treatment. Expert Review of Clinical Immunology 1:3, pages 459-473.
Read now
Read now
Articles from other publishers (15)
Wasuchon Chaichan, Chidchanok Ruengorn, Kednapa Thavorn, Brian Hutton, Jacek C. Szepietowski, Jonathan A. Bernstein, Mati Chuamanochan & Surapon Nochaiwong. (2023) Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. The Journal of Allergy and Clinical Immunology: In Practice 11:8, pages 2365-2381.
Crossref
Crossref
I S Gushchin & I V Danilicheva. (2017) EBASTINE. A REASONABLE CHOICE. Russian Journal of Allergy 14:4-5, pages 89-97.
Crossref
Crossref
Maulina Sharma, Cathy Bennett, Ben Carter & Stuart N. Cohen. (2015) H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review. Journal of the American Academy of Dermatology 73:4, pages 710-716.e4.
Crossref
Crossref
Maulina Sharma, Cathy Bennett, Stuart N Cohen & Ben Carter. (2014) H1-antihistamines for chronic spontaneous urticaria. Cochrane Database of Systematic Reviews 2017:5.
Crossref
Crossref
T. Zuberbier, W. Aberer, R. Asero, C. Bindslev‐Jensen, Z. Brzoza, G. W. Canonica, M. K. Church, L. F. Ensina, A. Giménez‐Arnau, K. Godse, M. Gonçalo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, A. H. Abdul Latiff, P. Mathelier‐Fusade, M. Metz, S. S. Saini, M. Sánchez‐Borges, P. Schmid‐Grendelmeier, F. E. R. Simons, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, B. Wedi, X. J. Zhu, A. Nast & M. Maurer. (2014)
Methods report on the development of the 2013 revision and update of the
EAACI
/
GA
2
LEN
/
EDF
/
WAO
guideline for the definition, classification, diagnosis, and management of urticaria
. Allergy 69:7.
Crossref
Crossref
B. Wedi, D. Wieczorek, U. Raap & A. Kapp. (2013) Urtikaria … und die Therapie versagt!Urticaria … and treatment fails. Der Hautarzt 64:9, pages 656-663.
Crossref
Crossref
T. Zuberbier, R. Asero, C. Bindslev‐Jensen, G. Walter Canonica, M. K. Church, A. M. Giménez‐Arnau, C. E. H. Grattan, A. Kapp, M. Maurer, H. F. Merk, B. Rogala, S. Saini, M. Sánchez‐Borges, P. Schmid‐Grendelmeier, H. Schünemann, P. Staubach, G. A. Vena & B. Wedi. (2009) EAACI/GA²LEN/EDF/WAO guideline: management of urticaria. Allergy 64:10, pages 1427-1443.
Crossref
Crossref
J. Sastre. (2008) Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy 63, pages 1-20.
Crossref
Crossref
Rosa Antonijoan, Consuelo García-Gea, Montserrat Puntes, Joselin Pérez, Ramón Esbrí, Cristina Serra, Josep Fortea & Manuel J. Barbanoj. (2007) Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): A randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clinical Therapeutics 29:5, pages 814-822.
Crossref
Crossref
Rosa M Antonijoan, Consuelo Garc??a-Gea, Montserrat Puntes, Marta Valle, Ramon Esbri, Josep Fortea & Manuel J Barbanoj. (2007) A Comparison of Ebastine 10mg Fast-Dissolving Tablet with Oral Desloratadine and Placebo in Inhibiting the Cutaneous Reaction to??Histamine in Healthy Adults. Clinical Drug Investigation 27:7, pages 453-461.
Crossref
Crossref
T. Zuberbier, C. Bindslev-Jensen, W. Canonica, C. E. H. Grattan, M. W. Greaves, B. M. Henz, A. Kapp, M. M. A. Kozel, M. Maurer, H. F. Merk, T. Schafer, D. Simon, G. A. Vena & B. Wedi. (2006) EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 61:3, pages 321-331.
Crossref
Crossref
Masaaki Tagawa, Michiko Kano, Nobuyuki Okamura, Makoto Higuchi, Michiaki Matsuda, Yasuyuki Mizuki, Hiroyuki Arai, Toshihiko Fujii, Sadao Komemushi, Masatoshi Itoh, Hidetada Sasaki, Takehiko Watanabe & Kazuhiko Yanai. (2008) Differential cognitive effects of ebastine and (+)‐chlorpheniramine in healthy subjects: Correlation between cognitive impairment and plasma drug concentration. British Journal of Clinical Pharmacology 53:3, pages 296-304.
Crossref
Crossref
Masaaki Tagawa, Michiko Kano, Nobuyuki Okamura, Makoto Higuchi, Michiaki Matsuda, Yasuyuki Mizuki, Hiroyuki Arai, Ren Iwata, Toshihiko Fujii, Sadao Komemushi, Tatsuo Ido, Masatoshi Itoh, Hidetada Sasaki, Takehiko Watanabe & Kazuhiko Yanai. (2001)
Neuroimaging of histamine H
1
-receptor occupancy in human brain by positron emission tomography (PET): A comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine
. British Journal of Clinical Pharmacology 52:5, pages 501-509.
Crossref
Crossref
Anne K. Ellis & James H. Day. (2008) Second‐ and third‐generation antihistamines in the treatment of urticaria. Dermatologic Therapy 13:4, pages 327-336.
Crossref
Crossref
Nelly Frossard, Michel Melac, Ouardia Benabdesselam & Gabrielle Pauli. (1998) Consistency of the Efficacy of Cetirizine and Ebastine on Skin Reactivity. Annals of Allergy, Asthma & Immunology 80:1, pages 61-65.
Crossref
Crossref